- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06285071
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
March 29, 2024 updated by: Novo Nordisk A/S
A Multi-centre, Open-label, Single-arm, Non-interventional Post-marketing Study to Investigate Safety and Clinical Parameters of Alhemo® Under Routine Clinical Practice in Japan
The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan.
Participants will get Alhemo® as prescribed by the study doctor.
The study will last for about 2 years.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
23
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
Tokyo
-
Toshima, Tokyo, Japan
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Participants with haemophilia A or haemophilia B with inhibitors will be treated with commercially available concizumab according to routine clinical practice at the discretion of the treating physician.
Description
Inclusion Criteria:
- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
- The decision to initiate treatment with commercially available Alhemo® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study
- Male or female patients, regardless of age
- Diagnosis with HAwI/HBwI
Exclusion Criteria:
- Previous participation in this study. Participation is defined as having given informed consent in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Concizumab
Participants with haemophilia A or haemophilia B with inhibitors will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician.
Recruitment will be completed after 4.5 years from the launch of Concizumab.
The observation period for each participant is 2 years.
Total duration of this study is about 6.5 years.
|
Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician.
The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse reaction (AR)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of ARs.
|
From baseline (week 0) to end of study (week 104)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of serious adverse reaction (SAR)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of SARs.
|
From baseline (week 0) to end of study (week 104)
|
Number of serious adverse event (SAE)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of SAEs.
|
From baseline (week 0) to end of study (week 104)
|
Number of thromboembolic adverse event (AE)
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of thromboembolic AEs.
|
From baseline (week 0) to end of study (week 104)
|
Number of shock/anaphylaxis AE
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of shock/anaphylaxis AEs.
|
From baseline (week 0) to end of study (week 104)
|
Number of treated spontaneous and traumatic bleeding episodes
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of bleeding episodes.
|
From baseline (week 0) to end of study (week 104)
|
Number of treated spontaneous and traumatic target joint bleeding episodes
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of bleeding episodes.
|
From baseline (week 0) to end of study (week 104)
|
Number of all treatment requiring bleeding episode
Time Frame: From baseline (week 0) to end of study (week 104)
|
Measured as count of bleeding episodes.
|
From baseline (week 0) to end of study (week 104)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 30, 2024
Primary Completion (Estimated)
April 30, 2030
Study Completion (Estimated)
April 30, 2030
Study Registration Dates
First Submitted
February 13, 2024
First Submitted That Met QC Criteria
February 26, 2024
First Posted (Actual)
February 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 1, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN7415-7557
- U1111-1274-4740 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Haemophilia A
-
Novo Nordisk A/SCompletedHaemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BFrance, United States, India, Mexico, United Kingdom, Netherlands, Sweden, Korea, Republic of, Spain, Switzerland, Serbia, Turkey, Bulgaria, Italy, Japan, Poland, South Africa, Croatia, Algeria, Australia, Bosnia and Herzegovina, ... and more
-
Novo Nordisk A/SCompletedEpidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (HAEMOcare)Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BIndia, Morocco, South Africa, Oman
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BSpain
-
Novo Nordisk A/SRecruitingHaemophilia A With Inhibitors | Haemophilia AUnited States, Korea, Republic of, France, Spain, Romania, Canada, Taiwan, China, Lithuania, Netherlands, India, South Africa, Russian Federation, Austria, Belgium, Czechia, Denmark, Germany, Ireland, Italy, Japan, Latvia, Malaysia, M... and more
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
Novo Nordisk A/SWithdrawnHealthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia B | Relatives to/Carers of PatientsSpain, Canada, United Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Haemophilia A | Haemophilia BUnited States
-
Novo Nordisk A/SRecruitingHaemophilia A With Inhibitors | Haemophilia ATaiwan, Canada, Spain, Netherlands, Korea, Republic of, India, United States, United Kingdom, Portugal, Lithuania, Turkey, China, South Africa, Ireland, Italy, France, Japan, Poland, Belgium, Germany, Malaysia, Austria, Bulgaria, Denmark and more
-
Novo Nordisk A/SActive, not recruitingHaemophilia A With Inhibitors | Haemophilia ASpain, Korea, Republic of, Canada, United Kingdom, United States, Germany, South Africa, Italy, Austria, Belgium, France, Japan
Clinical Trials on Concizumab
-
Novo Nordisk A/SAvailableCongenital HaemophiliaUnited States, Bulgaria, Sweden
-
Novo Nordisk A/SActive, not recruitingHaemophilia A With Inhibitors | Haemophilia B With InhibitorsSpain, Korea, Republic of, India, Australia, United Kingdom, Russian Federation, Poland, Ukraine, Thailand, Mexico, United States, Turkey, Japan, South Africa, Serbia, France, Croatia, Denmark, Algeria, Bulgaria, Malaysia, Portugal, Slovaki... and more
-
Novo Nordisk A/SRecruitingHaemophilia A and B With and Without InhibitorsUnited States, Spain, Italy, Estonia, Thailand, Canada, India, Malaysia, United Kingdom, Turkey, South Africa, Lebanon, Bosnia and Herzegovina, Bulgaria, France, Greece, Japan, Lithuania, Norway, Poland, Romania, Russian Federation, Swede... and more
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsUnited States, Austria, Spain, Japan, Croatia, Italy, United Kingdom, Israel, Sweden, Ukraine, Malaysia, Greece, Denmark, Canada
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia AUnited States, Netherlands, Austria, Spain, Poland, United Kingdom, Croatia, Germany, Malaysia, Australia, France, Israel, Thailand, Ukraine, Turkey
-
Novo Nordisk A/SActive, not recruitingHaemophilia A Without Inhibitors | Haemophilia B Without InhibitorsSpain, United States, Korea, Republic of, United Kingdom, Australia, Lithuania, France, Turkey, India, Estonia, Russian Federation, Ukraine, Mexico, Japan, South Africa, Serbia, Canada, Croatia, Algeria, Bosnia and Herzegovina, ... and more
-
Novo Nordisk A/SCompletedHaemophilia A | HaemostasisUnited Kingdom, France, United States, Sweden, Spain, Turkey, Japan, Italy, Germany, Thailand, Ukraine
-
University Hospital, BordeauxCompletedGlanzmann ThrombastheniaFrance